Abstract
Substance Abuse is epidemic in our society and despite systems and policies at every level to ensure safe dispensing of medicines; many problems exist, resulting in tragic morbidity and mortality in every community in the United States. This chapter examines the role of the Pharmacists, in terms of safeguarding the many potent agents available through prescriptions and nonprescriptions, illicit availability, and systems available to minimize risks such as drug testing and Risk Evaluation & Mitigation Strategies (REMS). The role of the Pharmacist includes effective communication with other healthcare professionals and utilization of Prescription Drug Monitoring Programs (PDMP), which allow for identification of patients who are also being prescribed substances of abuse by other Physicians within the same state. The Pharmacist plays a critical role in ensuring safe prescribing practice of drugs of abuse and in identification of patients with Substance Abuse issues.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wagner JC. Abuse of drugs used to enhance athletic performance. Am J Hosp Pharm. 1989;46(10):2059–67.
Kim D. Practical use and risk of modafinil, a novel waking drug. Environ Health Toxicol. 2012;27:e2012007. doi:10.5620/eht.2012.27.e2012007. Epub 2012 Feb 22.
FDA News Alert: Approved Risk Evaluation and Mitigation Strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications. http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm. Accessed 9 July 2012.
Matthews ML. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies. J Am Pharm Assoc. 2003;53(1):e1–7. doi:10.1331/JAPhA.2013.12025. 2013 Jan–Feb.
Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27(9):808–16. doi:10.1177/0269881113493364. Epub 2013 Jun 19.
Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag. 2011;7(3):193–202. 2011 May–Jun.
U.S. Food and Drug Administration (FDA) voted against recommending approval of the painkiller Zohydro ER on 12-10-2010. http://www.drugfree.org/join-together/addiction/fda-panel-votes-against-recommending-zohydro-for-approval
FDA Rejects Acurox by a 19 to 1 vote, questions about whether it truly is an effective abuse deterrent. http://www.fiercebiotech.com/story/19-1-vote-fda-panel-rejects-acurox/2010-04-23. Accessed 23 April 2010.
Edwards RR, Wasan AD, Michna E, Greenbaum S, Ross E, Jamison RN. Elevated pain sensitivity in chronic pain patients at risk for opioid misuse. J Pain. 2011;12(9):953–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kaye, A.M., Kaye, A.D. (2015). Appropriate Dispensing of Prescription Medications and Recognition of Substance Abuse: The Pharmacist’s Perspective. In: Kaye, A., Vadivelu, N., Urman, R. (eds) Substance Abuse. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1951-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1951-2_21
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1950-5
Online ISBN: 978-1-4939-1951-2
eBook Packages: MedicineMedicine (R0)